AAIPharma reported a definitive agreement to acquire Cvitkovic & Associes Consultants (CAC), an international contract research organization specializing in oncology drug development and medical consulting. The acquisition of CAC provides AAIPharma with additional therapeutic expertise and strengthens its global clinical development business. The acquisition is expected to close in the fourth quarter of 2006.
CAC has 10 years of experience in performing lead assessment of new analogues of established drugs, as well as novel target-oriented compounds. The company’s knowledge in cancer therapies includes cytotoxics, cytostatics, Mabs, cell-based therapies, vaccines, antiangiogenic agents, apoptosis inducers, and hormonal therapies.
CAC brings to AAIPharma specialized, full-service capabilities in the early stages of oncology drug development, as well as in conducting large international Phase IIb/III studies.
“Having established our own model of clinical CRO services, based on therapeutic specificity combined with medical and scientific know-how, CAC has now reached the limits of its organic growth,” explains Esteban Cvitkovic, CAC chairman and founder.
CAC is headquartered in Paris and has offices in the U.S., Europe, and Latin America.